Compare Boston Beer Company Inc (SAM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs TG Therapeutics Inc — how do they compare? Boston Beer Company Inc trades at $170.51 (market cap $1.76B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 4.6× Boston Beer Company Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Boston Beer Company Inc for 59 Days and TG Therapeutics Inc for 16 Days on average.
| SAM | TGTX | |
|---|---|---|
Market Cap | $1.76B | $8.16B |
Volume | 264,496 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $59.06 |
52-Week Low | $161.08 | $26.94 |
Typical Hold Time | 59 Days | 16 Days |
Enterprise Value | $1.53B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Beer Company (SAM) trades at $171.17, up 1.79% with a bullish technical signal despite recent earnings misses. The stock shows mixed fundamentals with a P/E of 22.66 and negative net margin of -3.64%, though operating cash flow remains strong at $270M. Recent news highlights brand innovation including new cocktail products and marketing partnerships, while analyst consensus leans heavily toward Hold with a $204.44 price target.
SAM faces headwinds from declining volumes and cost pressures, but brand investments and new product launches offer growth potential. The stock trades near analyst low targets with institutional interest growing, though profitability concerns and competitive pressures present significant risks for investors seeking turnaround opportunities in the challenging beverage sector.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
